Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells.

Retinoids modulate the growth and differentiation of cancer cells presumably by activating gene transcription via the nuclear retinoic acid receptor (RAR) alpha, beta, and gamma and retinoid X receptor (RXR) alpha, beta, and gamma. We analyzed the effects of 38 RAR-selective and RXR-selective retinoids on the proliferation of 10 human head and neck squamous cell carcinoma (HNSCC) cell lines. All of these cell lines expressed constitutively all of the receptor subtypes except RARbeta, which was detected in only two of them. Most of the RAR-selective retinoids inhibited the growth of HNSCC cells to varying degrees, whereas the RXR-selective retinoids showed very weak or no inhibitory effects. Three RAR antagonists suppressed growth inhibition by RAR-selective agonists, as well as by RAR/RXR panagonists such as 9-cis-retinoic acid. Combinations of RXR-selective and RAR-selective retinoids exhibited additive growth-inhibitory effects. Furthermore, we found that CD437, the most potent growth-inhibitory retinoid induced apoptosis and up-regulated the expression of several apoptosis-related genes in HNSCC cells. These results indicate that: (a) retinoid receptors are involved in the growth-inhibitory effects of retinoids; (b) RXR-RAR heterodimers rather than RXR-RXR homodimer are the major mediators of growth inhibition by retinoids in HNSCC cells; and (c) induction of apoptosis can account for one mechanism by which retinoids such as CD437 inhibit the growth of HNSCC cells. Finally, these studies identified several synthetic retinoids, which are much more effective than the natural RAs and can be good candidates for chemoprevention and therapy of head and neck cancers.

[1]  R. Lotan,et al.  Implication of c-Myc in apoptosis induced by the retinoid CD437 in human lung carcinoma cells , 1999, Oncogene.

[2]  R. Lotan,et al.  Implication of p53 in growth arrest and apoptosis induced by the synthetic retinoid CD437 in human lung cancer cells. , 1999, Cancer research.

[3]  R. Lotan,et al.  Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells , 1999, Oncogene.

[4]  R. Lotan,et al.  Differential responses of normal, premalignant, and malignant human bronchial epithelial cells to receptor-selective retinoids. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[6]  C. Glass,et al.  Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators , 1998, Nature.

[7]  John Calvin Reed,et al.  Molecular Determinants of AHPN (CD437)-Induced Growth Arrest and Apoptosis in Human Lung Cancer Cell Lines , 1998, Molecular and Cellular Biology.

[8]  A. Fornace,et al.  p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. , 1998, Cancer research.

[9]  M. Dawson,et al.  Inhibition of cell proliferation and induction of apoptosis by the retinoid AHPN in human lung carcinoma cells. , 1998, American Journal of Respiratory Cell and Molecular Biology.

[10]  R. Lotan,et al.  Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. , 1997, Cancer research.

[11]  A. Rishi,et al.  Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptor-independent pathway. , 1997, Blood.

[12]  Christopher K. Glass,et al.  The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function , 1997, Nature.

[13]  I. Krantz,et al.  KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene , 1997, Nature Genetics.

[14]  D. Schadendorf,et al.  Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo , 1996, The Journal of cell biology.

[15]  P. Chambon.  A decade of molecular biology of retinoic acid receptors , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  R. Lotan,et al.  Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  Y. Hashimoto,et al.  [Retinoid antagonists]. , 1996, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[18]  B. Shroot,et al.  Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes. , 1995, Journal of medicinal chemistry.

[19]  P. Chambon,et al.  Synergistic activation of retinoic acid (RA)-responsive genes and induction of embryonal carcinoma cell differentiation by an RA receptor alpha (RAR alpha)-, RAR beta-, or RAR gamma-selective ligand in combination with a retinoid X receptor-specific ligand , 1995, Molecular and cellular biology.

[20]  B. O’Malley,et al.  Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.

[21]  Y. Hashimoto,et al.  Synergists for retinoid in cellular differentiation of human promyelocytic leukemia cells HL-60. , 1995, Chemical & pharmaceutical bulletin.

[22]  Myles Brown,et al.  Polarity-specific activities of retinoic acid receptors determined by a co-repressor , 1995, Nature.

[23]  M. Pfahl,et al.  Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity. , 1995, Journal of medicinal chemistry.

[24]  M. Sheikh,et al.  p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. , 1995, Oncogene.

[25]  M. Garst,et al.  Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids. , 1995, Journal of medicinal chemistry.

[26]  P. Chambon,et al.  RAR‐specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage‐independent cell proliferation. , 1995, The EMBO journal.

[27]  P. Chambon,et al.  Endogenous Retinoic Acid Receptor (RAR)-Retinoid X Receptor (RXR) Heterodimers Are the Major Functional Forms Regulating Retinoid-responsive Elements in Adult Human Keratinocytes , 1995, The Journal of Biological Chemistry.

[28]  R. Lotan,et al.  Enhanced efficacy of combinations of retinoic acid- and retinoid X receptor-selective retinoids and alpha-interferon in inhibition of cervical carcinoma cell proliferation. , 1995, Cancer research.

[29]  S. Lippman,et al.  Head and Neck Cancer , 1993, Cancer Treatment and Research.

[30]  A. Fanjul,et al.  A new class of retinoids with selective inhibition of AP-1 inhibits proliferation , 1994, Nature.

[31]  P. Chambon,et al.  Modulation by retinoic acid (RA) of squamous cell differentiation, cellular RA-binding proteins, and nuclear RA receptors in human head and neck squamous cell carcinoma cell lines. , 1994, Cancer research.

[32]  L Zhang,et al.  Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. , 1994, Journal of medicinal chemistry.

[33]  Z. Shao,et al.  Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor-alpha acquire sensitivity to growth inhibition by retinoids. , 1994, The Journal of biological chemistry.

[34]  H. Koeffler,et al.  Myeloid differentiation mediated through retinoic acid receptor/retinoic X receptor (RXR) not RXR/RXR pathway. , 1994, Blood.

[35]  M. Pfahl.  Nuclear receptor/AP-1 interaction. , 1993, Endocrine reviews.

[36]  J. Lehmann,et al.  Conformational effects on retinoid receptor selectivity. 1. Effect of 9-double bond geometry on retinoid X receptor activity. , 1993, Journal of medicinal chemistry.

[37]  J. Lehmann,et al.  Retinoids selective for retinoid X receptor response pathways. , 1992, Science.

[38]  J. Lehmann,et al.  Homodimer formation of retinoid X receptor induced by 9-cis retinoic acid , 1992, Nature.

[39]  B. Shroot,et al.  Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma. , 1992, Biochemical and biophysical research communications.

[40]  R. Evans,et al.  Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. , 1992, Genes & development.

[41]  K. Umesono,et al.  Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling , 1992, Nature.

[42]  M. Pfahl,et al.  Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors , 1992, Nature.

[43]  C. Glass,et al.  RXRβ: A coregulator that enhances binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate response elements , 1991, Cell.

[44]  M. Karin,et al.  The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. , 1991, Biochimica et biophysica acta.

[45]  L. M. Luca,et al.  Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. , 1991 .

[46]  B. Shroot,et al.  Selective high affinity retinoic acid receptor alpha or beta-gamma ligands. , 1991, Molecular pharmacology.

[47]  J. Lehmann,et al.  Identification of retinoids with nuclear receptor subtype-selective activities. , 1991, Cancer research.

[48]  J. Wagner,et al.  In vitro radiation resistance among cell lines established from patients with squamous cell carcinoma of the head and neck , 1991, Cancer.

[49]  R. Lotan,et al.  Inhibition of growth and squamous‐cell differentiation markers in cultured human head and neck squamous carcinoma cells by β‐all‐trans retinoic acid , 1990 .

[50]  R. Lotan,et al.  Inhibition of growth and squamous-cell differentiation markers in cultured human head and neck squamous carcinoma cells by beta-all-trans retinoic acid. , 1990, International journal of cancer.

[51]  J. Lehmann,et al.  Nuclear retinoic acid receptors: cloning, analysis, and function. , 1990, Methods in enzymology.

[52]  R. Lotan,et al.  Modulation of growth, differentiation and glycoprotein synthesis by β‐ALL‐trans retinoic acid in a multicellular tumor spheroid model for squamous carcinoma of the head and neck , 1989, International journal of cancer.

[53]  P. Chambon,et al.  A third human retinoic acid receptor, hRAR-gamma. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Y. Hashimoto,et al.  Retinobenzoic acids. 2. Structure-activity relationships of chalcone-4-carboxylic acids and flavone-4'-carboxylic acids. , 1989, Journal of medicinal chemistry.

[55]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[56]  S. Pathak,et al.  Establishment and characterization of two new squamous cell carcinoma cell lines derived from tumors of the head and neck. , 1988, Cancer research.

[57]  P. Chambon,et al.  Identification of a second human retinoic acid receptor , 1988, Nature.

[58]  Pierre Chambon,et al.  A human retinoic acid receptor which belongs to the family of nuclear receptors , 1987, Nature.

[59]  E. Lane,et al.  Characteristics of four new human cell lines derived from squamous cell carcinomas of the head and neck. , 1985, Journal of the National Cancer Institute.

[60]  M. Reiss,et al.  Modulation of the terminal differentiation of human squamous carcinoma cells in vitro by all-trans-retinoic acid. , 1985, Journal of the National Cancer Institute.

[61]  T. Carey,et al.  Human squamous cell carcinoma. Establishment and characterization of new permanent cell lines. , 1981, Archives of otolaryngology.